Regeneron Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	13,640	13,687	12,581	11,808	15,791
Other Revenue	702.6	515	536.1	365.1	281.2
Revenue	14,343	14,202	13,117	12,173	16,072
Revenue Growth (YoY)	0.99%	8.27%	7.76%	-24.26%	89.14%
Cost of Revenue	7,951	7,103	6,255	5,153	5,298
Gross Profit	6,392	7,100	6,862	7,020	10,774
Selling, General & Admin	2,674	2,954	2,631	2,116	1,825
Other Operating Expenses	-10	-	-2.1	-89.9	-45.6
Operating Expenses	2,664	2,954	2,629	2,026	1,779
Operating Income	3,728	4,145	4,233	4,994	8,995
Interest Expense	-43.8	-55.2	-73	-59.4	-57.3
Interest & Investment Income	-	711.4	495.9	160.1	45.8
Currency Exchange Gain (Loss)	-	-0.5	-12.9	50.2	0.4
Other Non Operating Income (Expenses)	750.5	15.8	-20	8.8	4
EBT Excluding Unusual Items	4,435	4,817	4,623	5,154	8,988
Merger & Restructuring Charges	-0.8	-	-	-	-
Gain (Loss) on Sale of Investments	946.1	117.7	-237.8	-39.8	386.1
Legal Settlements	-25	-	-	-	-
Other Unusual Items	-	-53.4	-	-	-
Pretax Income	5,231	4,780	4,199	4,859	9,326
Income Tax Expense	725.8	367.3	245.7	520.4	1,251
Net Income	4,505	4,413	3,954	4,338	8,075
Net Income to Common	4,505	4,413	3,954	4,338	8,075
Net Income Growth	2.09%	11.61%	-8.87%	-46.28%	129.86%
Shares Outstanding (Basic)	105	108	107	107	106
Shares Outstanding (Diluted)	109	115	114	114	112
Shares Change (YoY)	-5.65%	1.23%	0.18%	1.16%	-2.52%
EPS (Basic)	43.07	40.90	37.05	40.51	76.40
EPS (Diluted)	41.48	38.34	34.77	38.22	71.97
EPS Growth	8.19%	10.27%	-9.03%	-46.89%	135.81%
Free Cash Flow	-	3,665	3,875	4,425	6,529
Free Cash Flow Per Share	-	31.84	34.08	38.98	58.19
Dividend Per Share	3.520	-	-	-	-
Gross Margin	44.57%	49.99%	52.32%	57.67%	67.04%
Operating Margin	25.99%	29.19%	32.27%	41.03%	55.97%
Profit Margin	31.41%	31.07%	30.14%	35.64%	50.24%
Free Cash Flow Margin	-	25.80%	29.54%	36.35%	40.63%
EBITDA	4,259	4,628	4,654	5,335	9,281
EBITDA Margin	29.70%	32.59%	35.48%	43.83%	57.75%
D&A For EBITDA	531.6	482.9	421	341.4	286.2
EBIT	3,728	4,145	4,233	4,994	8,995
EBIT Margin	25.99%	29.19%	32.27%	41.03%	55.97%
Effective Tax Rate	13.88%	7.68%	5.85%	10.71%	13.41%
Revenue as Reported	14,343	14,202	13,117	12,173	16,072

Updated Jan 30, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q